Ipsen S.A. (IPN.PA)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. David Loew | MD, CEO & Director | 2.22M | -- | 1967 |
| Mr. Aymeric Le Chatelier | Executive VP & CFO | 731.25k | -- | 1969 |
| Dr. Aidan Murphy Ph.D. | Executive VP and Head of Technical Operations | -- | -- | 1966 |
| Mr. Craig Marks | Vice-President of Investor Relations | -- | -- | -- |
| Mr. Francois Garnier | Executive VP of Legal Affairs, General Counsel & Chief Business Ethics Officer | -- | -- | 1962 |
| Ms. Gwenan White | Executive VP and Head of Communications, Public Affairs & Sustainability | -- | -- | -- |
| Mr. Regis Mulot | Executive VP & Chief Human Resources Officer | -- | -- | 1966 |
| Ms. Dominique Bery | Head of Nordics & Baltics | -- | -- | 1971 |
| Mr. Bartosz Bednarz D.D.S. | Executive VP and Head of Global Product & Portfolio Strategy | -- | -- | -- |
| Mr. Philippe Lopes-Fernandes CBO | Executive VP & Chief Business Officer | -- | -- | -- |
Ipsen S.A.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 5,325
Description
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
Corporate Governance
Recent Events
Recent Events Information Not Available
Upcoming Events
May 30, 2024
Ex-Dividend Date